Marc Darrow, MD, JD

Patients often come to us after one or more epidural steroid injections. Some had meaningful relief, but the pain returned. Others noticed little change and were told that surgery was the next step. Their question is understandable: If the injection did not solve the problem, what should happen next?

My concern is whether the treatment matches the structure causing the pain. An injection intended to reduce inflammation around a spinal nerve has a different purpose from treatment directed at a painful sacroiliac joint, facet joint, or ligament attachment. Before choosing another procedure, we need to reconsider what is actually hurting.

What epidural steroid injections can—and cannot—do

An epidural steroid injection places corticosteroid medication, sometimes with local anesthetic, into the space around the spinal nerves. It is intended to reduce inflammatory irritation. It does not mechanically remove a disc herniation, widen a narrowed spinal canal, or establish that damaged tissue has regenerated.

The 2025 American Academy of Neurology review included 90 randomized trials. For cervical and lumbar radiculopathy, injections probably improve pain and disability in the short term. Evidence was insufficient to establish long-term pain relief. For lumbar stenosis, possible disability benefits were identified, but short-term pain benefit was not established. The evidence search ended in January 2021, despite the review’s 2025 publication. (1)

These findings matter because temporary symptom relief and lasting surgery avoidance are different outcomes. A person may value several weeks of improved sleep or activity even when an injection does not change the underlying anatomy.

Do epidural injections reduce the need for surgery?

The most defensible answer is that reliable long-term surgery prevention has not been established. A review specifically examining surgery found no statistically significant long-term reduction in operations. A separate review found a short-term reduction in surgery risk for radiculopathy, supported by low-strength evidence, without a lasting reduction. (2) (3)

This does not mean every patient who receives an epidural will eventually need surgery. Some recover without an operation. It means we cannot promise that the injection itself prevents surgery. Improvement may reflect treatment, rehabilitation, natural recovery, or several factors together.

What the earlier studies on this page still teach us

A 2016 meta-analysis by Bhatia and colleagues found modest pain benefit from transforaminal steroid injections for disc-related radicular pain, without improvement in disability or surgery incidence in its pooled findings. That narrower conclusion should not be extended to every injection, diagnosis, or follow-up period. (4)

Leung and colleagues reported that immediate improvement after transforaminal injection did not establish a change in long-term surgical need. Their observational study illustrates the difference between a prompt response and a durable outcome. (5)

The SPORT subgroup analysis found no better short- or long-term outcomes among patients with lumbar disc herniation who received epidural injections. However, injection use was not randomly assigned in this subgroup comparison, and treatment preferences differed. It cannot prove that injections cause poor outcomes or that surgery is inevitable. (6)

Kennedy and colleagues found that symptom recurrence over at least five years was common after initially successful treatment. Yet relatively few patients reported current symptoms or needed further treatment at follow-up. A recurrence is not the same as continuous severe pain or an unavoidable operation. (7)

Why newer reviews can reach different conclusions

A 2025 BMJ review focused on chronic non-cancer spine pain. It found that epidural local anesthetic plus steroid probably provides little or no pain benefit compared with sham procedures for chronic radicular pain. (8)

That conclusion appears less favorable than the AAN findings. The reviews used different eligibility criteria, comparisons, and analytical methods. Patients should therefore hear a measured explanation: some groups obtain short-term benefit, but the expected size and durability of benefit remain uncertain. Neither review justifies a guarantee of surgery prevention.

When an epidural does not work, reconsider the pain source

A scan may show a disc bulge or spinal narrowing, but the clinical examination still matters. Pain traveling into the leg can arise from nerve-root irritation or referred pain from other structures. Back pain and leg pain can also have different contributors in the same person.

In our clinical approach, we consider the relationship between the symptoms, neurologic findings, movements that reproduce pain, and tenderness over the relevant structures. We also consider the sacroiliac region and soft-tissue attachments when the presentation warrants it. This is a diagnostic perspective, not proof that ligament weakness explains every failed epidural.

No improvement after an epidural does not, by itself, establish that the pain comes from a ligament or that a regenerative injection will work. It also does not automatically establish that surgery is necessary. Our related article discusses sacroiliac joint pain versus disc-related pain in greater detail.

Is there a stem cell or bone marrow concentrate connection?

Yes, but the connection requires precision. Bone marrow concentrate, or BMC, is a preparation made from a patient’s bone marrow. It contains a mixture of cells and signaling components, including a small population of mesenchymal stromal cells. It is not a purified stem cell preparation and is not interchangeable with a laboratory-expanded MSC product.

Dr. Darrow’s research targets structures outside the disc

In our 2018 report, four patients received BMC injections at muscle, fascia, and ligament attachments around the lumbar spine. At one year, all four reported reduced resting and activity-related pain, with a mean reported overall improvement of 80%. (9)

Those observations are relevant to the question of whether structures outside the disc can contribute to back pain. However, four patients without a control group cannot establish effectiveness, tissue regeneration, superiority to epidural steroids, or prevention of surgery. These were not epidural injections, and the results should not be presented as evidence for injecting BMC around spinal nerves.

A 2025 controlled trial gives a different and necessary perspective

A double-blind randomized trial tested intradiscal BMC for chronic discogenic low-back pain. BMC did not demonstrate superiority over a sham procedure for the reported pain and functional outcomes. (10)

This trial studied a different target from our attachment-site case series. It does not settle every question about BMC, but it limits claims that injecting bone marrow reliably repairs painful discs. Evidence for one preparation and anatomical target cannot simply be transferred to another.

Where do exosomes fit?

Exosomes are a type of extracellular vesicle: tiny particles released by cells that carry biological signals. They are not living stem cells. Researchers are investigating whether these signals can influence inflammation and tissue responses relevant to spinal pain.

Human evidence exists, but remains preliminary

A 2024 pilot study evaluated a bone marrow MSC-derived extracellular-vesicle investigational product injected into lumbar facet joints in 20 adults. Pain and disability scores improved during three months of follow-up, and no adverse events were reported during that period. (11)

This is a research tie-in worth discussing, but its limitations are substantial. Without a control group, the study cannot separate a product effect from placebo effects, symptom fluctuation, or other influences. Twenty participants followed for three months cannot establish long-term safety or detect uncommon complications. The study did not establish surgery avoidance, and facet-joint injections are not equivalent to epidural or intradiscal injections.

The appropriate conclusion is that extracellular-vesicle research offers a possible biological direction for future treatment development. It does not establish exosomes as a proven replacement for an epidural, BMC, or surgery.

FDA status is part of the evidence discussion

The FDA states that there are no FDA-approved exosome products and that regenerative medicine products have not been approved for orthopedic conditions such as disc disease or back pain. A published pilot study does not establish approval or authorization for routine commercial use. (12)

We should therefore discuss exosomes as investigational research here, without implying that an unapproved product is an established treatment offered by our clinic.

How these approaches differ

Approach Relevant question What is not established
Epidural steroid injection Can reducing nerve-root inflammation improve symptoms? Reliable long-term surgery prevention
BMC at soft-tissue attachments Could targeting a suspected extra-discal pain source help? Effectiveness from an uncontrolled four-patient report
Intradiscal BMC Does injecting a painful disc outperform sham treatment? Superiority in the cited 2025 trial
MSC-derived extracellular vesicles Can cell-derived signals safely improve spinal pain? Durable efficacy, broad safety, or surgery prevention from the small facet pilot

What about risks and surgery?

Epidural injections are invasive procedures. The FDA has addressed rare serious neurologic complications associated with epidural corticosteroid injections. Risk assessment should account for the procedure, technique, medication, and patient’s medical circumstances. A balanced discussion should acknowledge these risks without suggesting that catastrophic injury is a usual outcome. (13)

Surgery can be appropriate when symptoms and neurologic findings match a surgically treatable problem. Persistent pain after surgery has multiple possible explanations; it should not automatically be attributed to untreated ligament laxity.

New bowel or bladder dysfunction, saddle numbness, or rapidly worsening leg weakness requires urgent medical evaluation. These symptoms should not be managed by waiting for a regenerative procedure.

For a broader discussion of narrowing around spinal nerves, see our article on lumbar spinal stenosis treatment options.

The decision begins with a diagnosis

An epidural may offer temporary relief for selected patients. Its failure does not identify the next treatment by itself. The next decision should depend on the suspected pain source, neurologic status, previous response, and evidence for the specific intervention being considered.

That same standard applies to BMC and exosomes. Biological plausibility and encouraging early observations are reasons to study an approach. They are not guarantees of healing or a way to promise that surgery can be avoided.

References

1 Armon C, Narayanaswami P, Potrebic S, et al. Epidural Steroids for Cervical and Lumbar Radicular Pain and Spinal Stenosis Systematic Review Summary: Report of the AAN Guidelines Subcommittee. Neurology. 2025;104(5):e213361. doi:10.1212/WNL.0000000000213361.

2 Bicket MC, Horowitz JM, Benzon HT, Cohen SP. Epidural injections in prevention of surgery for spinal pain: systematic review and meta-analysis of randomized controlled trials. Spine J. 2015;15(2):348–362. doi:10.1016/j.spinee.2014.10.011.

3 Chou R, Hashimoto R, Friedly J, et al. Epidural Corticosteroid Injections for Radiculopathy and Spinal Stenosis: A Systematic Review and Meta-analysis. Ann Intern Med. 2015;163(5):373–381. doi:10.7326/M15-0934.

4 Bhatia A, Flamer D, Shah PS, Cohen SP. Transforaminal Epidural Steroid Injections for Treating Lumbosacral Radicular Pain from Herniated Intervertebral Discs: A Systematic Review and Meta-Analysis. Anesth Analg. 2016;122(3):857–870. doi:10.1213/ANE.0000000000001155.

5 Leung SM, Chau WW, Law SW, Fung KY. Clinical value of transforaminal epidural steroid injection in lumbar radiculopathy. Hong Kong Med J. 2015;21(5):394–400. doi:10.12809/hkmj144310.

6 Radcliff K, Hilibrand A, Lurie JD, et al. The impact of epidural steroid injections on the outcomes of patients treated for lumbar disc herniation: a subgroup analysis of the SPORT trial. J Bone Joint Surg Am. 2012;94(15):1353–1358. doi:10.2106/JBJS.K.00341.

7 Kennedy DJ, Zheng PZ, Smuck M, McCormick ZL, Huynh L, Schneider BJ. A minimum of 5-year follow-up after lumbar transforaminal epidural steroid injections in patients with lumbar radicular pain due to intervertebral disc herniation. Spine J. 2018;18(1):29–35.

8 Wang X, et al. Common interventional procedures for chronic non-cancer spine pain: a systematic review and network meta-analysis of randomised trials. BMJ. 2025;388:e079971. doi:10.1136/bmj-2024-079971.

9 Darrow M, Shaw B. Treatment of Lower Back Pain with Bone Marrow Concentrate. Biomed J Sci Tech Res. 2018;7(2). doi:10.26717/BJSTR.2018.07.001461.

10 Levi D, Tyszko S, Horn S, Pham N, Levin J. Bone marrow concentrate intradiscal injection for chronic discogenic low back pain: A double-blind randomized sham-controlled trial. Interv Pain Med. 2025;4:100611. doi:10.1016/j.inpm.2025.100611.

11 Wilson JE, Today BA, Salazar M, et al. Safety of bone marrow derived mesenchymal stem cell extracellular vesicle injection for lumbar facet joint pain. Regen Med. 2024;19(1):19–26. doi:10.2217/rme-2023-0110.

12 U.S. Food and Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. July 22, 2020. Accessed November 13, 2026.

13 U.S. Food and Drug Administration. Safe Use Initiative – Completed Projects. Epidural steroid injection safety project. Accessed November 13, 2026.